News

Virginia Catalyst announces Grant Round 16 awarded projects!

The Virginia Catalyst, also known as the Virginia Biosciences Health Research Corporation (VBHRC), today announced that it has awarded $3.18 million in grants to four life and bioscience projects in the Commonwealth of Virginia. These grants, which will be met with significant matching funds from partner companies, were awarded through Grant Round 16.

“Powerful collaborations between Virginia’s research universities and industry is resulting in major breakthroughs in medical diagnostics, devices, and drug discovery” said Mike Grisham, CEO of Virginia Catalyst. “It’s also generating significant

Through this 16th round of funding, Virginia Catalyst has awarded 65 grants totaling nearly $33 million, resulting in over $50 million in matching funds and over $600 million in follow-on funding to date.

Grant Round 16 awarded projects:

Project:  Readmission Risk Assessment through Physiological and Behavioral Health Monitoring using

VitalStream Wireless Platform

  • Company: Caretaker Medical (Charlottesville, VA)
  • University collaborators: University of Virginia and Virginia Tech
  • Funding amount: $800,000

Project:  Optimization and Commercialization of PRECYSE as a Novel Quality Control Solution for Next Generation Sequencing

  • Company: Evizia, Inc. (Charlottesville, VA)
  • Funding amount: $800,000
  • University collaborators: Virginia Commonwealth University and University of Virginia

Project:  Developing an exercise-mimetic to treat diabetes

  • Company: MGMedicine, Inc. (Charlottesville, VA)
  • University collaborators: University of Virginia and Virginia Tech
  • Funding amount: $780,000

Project:  First-in-Class Bifunctional Cytokine to Target Tissue Resident Tregs for the Treatment of Idiopathic Nephropathy and other Autoimmune Diseases

  • Company: SlateBio, Inc. (Charlottesville, VA)
  • University collaborators: University of Virginia and Virginia Commonwealth University
  • Funding amount: $800,000

 

Recent News

09/09/2025

ATCC Receives Contract to Advance Industrial Biomanufacturing and Produce Synthetic Aviation Fuel Precursors

ATCC, the world’s premier biological materials management and standards organization, today announced that it has been granted a contract with Capra Biosciences, a Virginia-based biotech company focused on the cost-competitive production of petrochemical replacements using its modular bioreactor platform. ATCC is supporting a contract with Capra to work on the Defense Advanced Research Projects Agency’s

09/05/2025

RIVANNA awarded $2.21 million NIH grant to develop pediatric lumbar puncture ultrasound guidance system

RIVANNA®, developers of world-first imaging-based medical technologies, has been awarded a $2.21 million Small Business Innovation Research (SBIR) Direct to Phase II (R44) grant from the National Cancer Institute (NCI) of the National Institutes of Health (NIH) to develop an ultrasound guidance solution for pediatric lumbar punctures (LPs) on its Accuro® 3S platform. Lumbar punctures

09/03/2025

Cupron Performance Additives (“Cupron”) announces new distribution relationship with Palmer Holland

Cupron Performance Additives (Cupron) announced today the launch of an exclusive distribution agreement with Palmer Holland, leading North American distributor of specialty additives for the engineered materials marketplace. Palmer Holland will distribute Cupron’s copper-based antimicrobial and anti-odor technologies into plastics, films, foams, and polymeric systems throughout North America. The Cupron line effectively complements Palmer Holland’s